MedKoo product information:

  AD-1001

Description of AD-1001: AD-1001 is

Current developer:    Intrexon Corporation.

AD-1001 is Intrexon’s lead activator ligand designed to tightly control the RheoSwitch Therapeutic System™ and its regulated expression domain. AD-1001 was the subject of a previous Phase 1A randomized, double-blinded, placebo-controlled, dose-escalation, safety study in 65 normal healthy male and female volunteers. Results demonstrated that AD-1001 was well tolerated at all dose levels studied, achieved steady-state pharmacokinetics, attained high serum bioavailability levels, and yielded a metabolic half-life consistent with once-a-day dosing.